

IFW  
MAIL STOP - PCT  
Docket No.: 27579U

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Inventor: ROSCHER, et al. Art Unit: XX  
Appl. No.: 10/589,871 Examiner: XX  
Appl. Filing Date: August 18, 2006 Confirm. No.: XX  
Intl. Appl. No.: PCT/EP2005/050799  
Intl. Appl. Filing Date: February 25, 2005  
For: **CICLESONIDE AND GLYCOPYRRONIUM COMBINATION**

**TRANSMITTAL LETTER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

1. Information Disclosure Statement; and
2. PTO Form-1449 with 48 references cited, and copies of 34 of the 48 references cited.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,  
**NATH & ASSOCIATES PLLC**

November 22, 2006

  
Gary M. Nath, Reg. No. 26,965  
Sheldon M. McGee, Reg. No. 50,454  
Customer No. 34375

Le



MAIL STOP - PCT  
Docket No.: 27579U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: ROSCHER, et al. Art Unit: XX  
Appl. No.: 10/589,871 Examiner: XX  
Appl. Filing Date: August 18, 2006 Confirm. No.: XX  
Intl. Appl. No.: PCT/EP2005/050799  
Intl. Appl. Filing Date: February 25, 2005  
For: **CICLESONIDE AND GLYCOPYRRONIUM COMBINATION**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

a. ☒ [XXX] The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

b. ☐ [ ] The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.

The enclosed statement is accompanied by [check one]:

☐ [ ] i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or

☐ [ ] ii. a check in the amount required by 37 C.F.R. 1.17(p).



g. ☒ Copies of the documents are attached herewith with a completed PTO Form-1449.

or

☐ Copies of the documents are not attached, with a completed PTO Form-1449 as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

and / or


☒ Copies of US Patents/Publications not attached, with a completed PTO Form-1449 as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,  
**NATH & ASSOCIATES PLLC**

November 22, 2006

  
Gary M. Nath, Reg. No. 26,965  
Sheldon M. McGee, Reg. No. 50,454  
Customer No. 34375

PTO FORM-1449

**INFORMATION DISCLOSURE  
CITATION**

Inventor: ROSCHER, et al.

Appl. No.:  
10/589,871Intl. Appl. No:  
PCT/EP2005/050799Art Unit:  
XXAppl. Filing  
Date:  
August 18, 2006Intl. Appl. Filing  
Date:  
February 25, 2005Examiner:  
XX  
Confirm. No:  
XX**U.S. PATENT DOCUMENTS**

Exam. Initial		Document No.	Issue/Public. Date	Inventor	Filed Date
	A1	2005/0026886	2/3/2005	Meade et al.	7/15/2004
	A2	2005/0175548	8/11/2005	Goede et al.	2/7/2005
	A3	6,302,331	10/16/2001	Dvorsky et al.	4/20/2000
	A4	6,645,466	11/11/2003	Keller et al.	11/10/1999
	A5	6,204,285	3/20/2001	Fabiano et al.	6/27/1997
	A6	6,454,193	9/24/2002	Busick et al.	4/20/2000
	A7	6,397,838	6/4/2002	Zimlich Jr. et al.	12/21/1999
	A8	5,263,475 (corresp. to EP0505321)	11/23/1993	Altermatt et al.	3/18/1992
	A9	2004/0266869 (corresp. to WO0247668)	12/30/2004	Montague et al.	12/12/2001
	A10	5,482,934 (corresp. to DE4129535)	1/9/1996	Calatayud et al.	7/20/1994
	A11	5,733,901 (corresp. to WO9422899)	3/31/1998	Gutterer	3/31/1994
	A12	6,307,060 (corresp. to WO9821183)	10/23/2001	Noe et al.	5/11/1999
	A13	6,455,524 (corresp. to WO0069468)	9/24/2002	Bozung et al.	5/9/2000
	A14	6,475,467 (corresp. to WO0007567)	11/5/2002	Keller et al.	8/2/1999

**FOREIGN PATENT DOCUMENTS**

Exam. Initial		Document No.	Public. Date	Country	Translation
	A15	02/36106 A2	5/10/2002	WO	Abstract
	A16	0 725 725 B1	8/14/1996	EP	N/A
	A17	02/083113 A2	10/24/2002	WO	N/A
	A18	0 505 321 A2	9/23/1992	EP	No
	A19	02/47668 A2	6/20/2002	WO	Abstract
	A20	247,680	2/25/1926	GB	N/A
	A21	41 29 535 A1	3/12/1992	DE	No
	A22	2006/003078 A1	1/12/2006	WO	N/A
	A23	95/02650 A1	1/26/1995	WO	N/A
	A24	94/22899 A1	10/13/1994	WO	Abstract
	A25	91/11495 A1	8/8/1991	WO	Abstract
	A26	93/11743 A1	6/24/1993	WO	N/A
	A27	91/14422 A1	10/3/1991	WO	N/A
	A28	91/04011 A1	4/4/1991	WO	N/A
	A29	91/11173 A1	8/8/1991	WO	N/A
	A30	98/52542 A1	11/26/1998	WO	N/A
	A31	0 553 298 B1	8/4/1993	EP	N/A
	A32	0 372 777 B1	6/13/1990	EP	N/A
	A33	98/00133 A1	1/8/1998	WO	N/A
	A34	98/21183 A1	5/22/1998	WO	Abstract
	A35	98/00132 A1	1/8/1998	WO	N/A
	A36	01/76575 A2	10/18/2001	WO	N/A
	A37	02/30394 A2	4/18/2002	WO	N/A
	A38	0 407 028 B2	1/9/1991	EP	N/A
	A39	0 691 865 B1	1/17/1996	EP	N/A
	A40	0 650 410 B1	5/3/1995	EP	N/A

NOV 22 2006

MAIL STOP - PCT  
Docket No.: 27579U

A41	00/69468 A1	11/23/2000	WO	Abstract
A42	92/11190 A2	7/9/1992	WO	N/A
A43	96/32150 A1	10/17/1996	WO	N/A
A44	00/07567 A1	2/17/2000	WO	Abstract
A45				

## OTHER

Exam. Initial	(Including Author, Title, Date, Pertinent Pages, etc.)			
A46	Mirakhur, R.K., et al., "Glycopyrrolate: pharmacology and clinical use", <u>Anaesthesia</u> , Vol. 38, pg. 1195-1204, (1983).			
A47	Levin, R.M., et al., "Direct Measurement of the Anticholinergic Activity of a Series of Pharmacological Compounds on the Canine and Rabbit Urinary Bladder", <u>The Journal of Urology</u> , Vol. 128, pg. 396-398, (1982).			
A48	Cooke, R.D., "Glycopyrrolate in bladder dysfunction", <u>SA Medical Journal</u> , Vol. 63, pg. 3, (1983).			
A49	Demian, J., et al., "High-Performance Liquid Chromatographic Separation of 3-[(Cyclopentylhydroxyphenyl-acetyl)oxy]-1,1-Dimethyl-pyrrolidinium Bromide Diastereomers", <u>Journal of Liquid Chromatography</u> , Vol. 13, No. 4, pg. 779-787, (1990).			

Examiner	Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP'609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.